EU Pharmacovigilance Strategy: Public consultation on draft legislative proposals

EUDG Enterprise and Industry wishes to consult stakeholders on legislative proposals to strengthen and rationalise the EU system of pharmacovigilance. The Commission services conducted a previous consultation, between 16 March 2006 and 12 May 2006, which sought stakeholders' views on the strengths and weaknesses of the current EU system of pharmacovigilance and how the system could be strengthened. The web-based consultation was supplemented by public workshops in April 2006, as well as, meetings with specific stakeholder groups. The consultation results were made public in February 2007 and at the same time, in response to the consultation outcome, Vice- President Verheugen announced its "Strategy to Better Protect Public Health by Strengthening and Rationalising EU Pharmacovigilance". The Strategy has two parts: 1. better implementation of the current framework and, 2. proposals for change to the legal framework. Details of both the 2006 consultation and the Strategy are available on the Commission's website.

This public consultation specifically addresses part 2 of the strategy, the proposals for changes to the legal framework. This consultation paper is organised in the following sections:

  • Section 1 introduces the consultation, explains how and by when to submit consultation responses and explains the next steps.
  • Section 2 provides a brief orientation on pharmacovigilance and the background to the strategy.
  • Section 3 presents the legislative strategy and the key proposals for legislative change.
  • Section 4 presents detailed proposals to change EU legal texts.
The public consultation is open from 4 December 2007 to 1 February 2008. Stakeholders may wish to comment on the key proposals presented in Section 3 or may prefer to comment on the detailed proposals to change EU legal texts presented in Section 4. All comments should be sent electronically to Dr Peter Arlett by 1 February 2008.

For further information, download PUBLIC CONSULTATION ON LEGISLATIVE PROPOSALS document (.pdf).

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...